N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzofuran-2-yl)phenyl]methyl]butanediamide | 220682-10-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: N1-[2(R)-hydroxy-1(S)-indanyl]-N4-hydroxy-2(R)-[[4-(benzofuran-2-yl)phenyl]methyl]butanediamide
• 英文别名: (2R)-2-[[4-(1-benzofuran-2-yl)phenyl]methyl]-N'-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide
• CAS: 220682-10-0
• 化学式: C₂₈H₂₆N₂O₅
• 分子量: 470.525
• InChiKey: JZLRKMKQGFICQV-CIXCFARBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  112
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Methods, compositions and compound assays for inhibiting amyloid-beta protein production
  申请人：Merchiers Gerard Pascal

  公开号：US20060281699A1

  公开（公告）日：2006-12-14

  A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of PROTEASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.
• US6576664B1
  申请人：——

  公开号：US6576664B1

  公开（公告）日：2003-06-10
• [EN] METHODS, COMPOSITIONS AND COMPOUND ASSAYS FOR INHIBITING AMYLOID-BETA PROTEIN PRODUCTION<br/>[FR] PROCEDES, COMPOSITIONS ET ESSAIS DE COMPOSES POUR L'INHIBITION DE LA PRODUCTION D'UNE PROTEINE AMYLOIDE-BETA
  申请人：GALAPAGOS GENOMICS NV

  公开号：WO2005108949A2

  公开（公告）日：2005-11-17

  A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of PROTEASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.